These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18693236)

  • 1. Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile.
    Stiefel U; Nerandzic MM; Koski P; Donskey CJ
    J Antimicrob Chemother; 2008 Nov; 62(5):1105-8. PubMed ID: 18693236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice.
    Stiefel U; Pultz NJ; Harmoinen J; Koski P; Lindevall K; Helfand MS; Donskey CJ
    J Infect Dis; 2003 Nov; 188(10):1605-9. PubMed ID: 14624388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration.
    Merrigan MM; Sambol SP; Johnson S; Gerding DN
    Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S46-50. PubMed ID: 19303570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
    Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2005 Jun; 55(6):974-82. PubMed ID: 15860551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.
    Stiefel U; Harmoinen J; Koski P; Kääriäinen S; Wickstrand N; Lindevall K; Pultz NJ; Bonomo RA; Helfand MS; Donskey CJ
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5190-1. PubMed ID: 16304203
    [No Abstract]   [Full Text] [Related]  

  • 6. Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.
    Stiefel U; Nerandzic MM; Pultz MJ; Donskey CJ
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4535-42. PubMed ID: 24867962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.
    Pultz NJ; Donskey CJ
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3529-32. PubMed ID: 16048976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The frequency of Clostridium difficile toxin in neutropenic and non-neutropenic patients with antibiotic-associated diarrhea and analysis of the risk factors].
    Tunçcan OG; Ulutan F; Karakuş R
    Mikrobiyol Bul; 2008 Oct; 42(4):573-83. PubMed ID: 19149078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile toxins and enterococcal translocation in vivo and in vitro.
    Feltis BA; Garni RM; Wells CL
    J Surg Res; 2001 May; 97(1):97-102. PubMed ID: 11319888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaerobic infections and Clostridium difficile colitis emerging during antibacterial therapy.
    Finegold SM
    Scand J Infect Dis Suppl; 1986; 49():160-4. PubMed ID: 3547621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?
    Kundrapu S; Sunkesula VC; Jury LA; Cadnum JL; Nerandzic MM; Musuuza JS; Sethi AK; Donskey CJ
    BMC Infect Dis; 2016 Apr; 16():159. PubMed ID: 27091232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonization dynamics of ampicillin-resistant Escherichia coli in the infantile colonic microbiota.
    Karami N; Hannoun C; Adlerberth I; Wold AE
    J Antimicrob Chemother; 2008 Oct; 62(4):703-8. PubMed ID: 18583327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile.
    Péchiné S; Janoir C; Boureau H; Gleizes A; Tsapis N; Hoys S; Fattal E; Collignon A
    Vaccine; 2007 May; 25(20):3946-54. PubMed ID: 17433506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
    Kaleko M; Bristol JA; Hubert S; Parsley T; Widmer G; Tzipori S; Subramanian P; Hasan N; Koski P; Kokai-Kun J; Sliman J; Jones A; Connelly S
    Anaerobe; 2016 Oct; 41():58-67. PubMed ID: 27262694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
    Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
    Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal beta-lactamase activity in ampicillin-induced, Clostridium difficile-associated ileocecitis.
    Rolfe RD; Finegold SM
    J Infect Dis; 1983 Feb; 147(2):227-35. PubMed ID: 6600772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active and passive immunization against Clostridium difficile diarrhea and colitis.
    Giannasca PJ; Warny M
    Vaccine; 2004 Feb; 22(7):848-56. PubMed ID: 15040937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transconjugation and genotyping of the plasmid-mediated AmpC beta-lactamase and extended-spectrum beta-lactamase genes in Klebsiella pneumoniae.
    Shi WF; Zhou J; Qin JP
    Chin Med J (Engl); 2009 May; 122(9):1092-6. PubMed ID: 19493446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.
    Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N
    J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative strategies for Clostridium difficile infection.
    Bauer MP; van Dissel JT
    Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S51-6. PubMed ID: 19303571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.